In Brief: Abbott Outlook; CFSAN’s Landa To Retire; FTC Claim Substantiation
This article was originally published in The Tan Sheet
Executive Summary
Abbott “on track” in China recovery; CFSAN seeks new director; FTC adds new substantiation elements to settlement; NAD advises iSatori to amend claims energy supplement claims; FDA wants proof deficiencies are corrected; and FDA warns about chelation supplement.